LipoScience (NASDAQ:LPDX) has developed a blood test (NMR LipoProfile) that has the potential to meaningfully improve outcomes for patients at risk of cholesterol-related cardiovascular problems, but it takes more than an FDA-approved test to make a business work. LipoScience is perilously close to becoming a company with a great future in its past, as the company continues to struggle to generate commercial interest in its test. A journal article based upon a retrospective analysis of LDL-P measurement could help spur interest and a takeover is a credible potential outcome, but LipoScience's current circumstances make this a highly speculative stock.
Can Q1 Become The Bottom?
After a drawn out and pretty ugly process of revisions, it looks like the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|